Afinitor gains KFDA approval to treat patients with advanced pancreatic neuroendocrine tumors
Published: 2011-11-30 06:56:00
Updated: 2011-11-30 06:56:00
Novartis Korea announced Monday that the Korea Food and Drug Administration has approved Afinitor (everolimus) tablets for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumors (NET) of pancreatic origin in adults with progressive disease.
The ap...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
